rc48-adc
Gastric Neoplasms
Seagen, a wholly owned subsidiary of Pfizerantibody_drug_conjugatePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Gastric Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
S-1 Merck Sharp & Dohme LLC | Phase 3 | BB |
Tislelizumab Jazz Pharmaceuticals | Phase 3 | B |
Zanidatamab Jazz Pharmaceuticals | Phase 3 | B |
Pyrotinib Jazz Pharmaceuticals | Phase 3 | B |
Shr-A1811 Haihua Yuan | Phase 2 | CCC |
Asg-5Me Seagen Inc. | Phase 1 | CC |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →